The Second Clinical Update in Hematology is organized by the Medicine Institute at (SKMC) on 28 April 2011 at the Crown Plaza Hotel, Abu Dhabi. Dr. Jorgen Kristensen, Consultant Hematologist at SKMC is leading the symposium and the division of Hematology of SKMC.
A wide range of topics and updates in the field of hematology will be discussed by the speakers, such as management of acute leukemia, applications of flow cytometry, transfusion safety, immune thrombocytopenia, spinal fluid in hematology, neutropenia, indications and usage of molecular diagnostics, heparin induced thrombocytopenia, investigation of abnormal coagulation profile and prevention of hospital acquired Venous Thromboembolism (VTE).
Dr. Atul Mehta, Chief Medical Officer at SKMC, believes that this meeting stresses the SKMC role as a provider of comprehensive state-of-the-art patient care services, and as an active promoter of continuous medical education (CME) and oncology and hematology services in Abu Dhabi. He said “SKMC is excelling in its oncology and hematology services employing highly skilled and compassionate medical staff and clinical team using a multidisciplinary team approach to provide the most advanced diagnostic procedures and treatments available today in a patient-family centered approach”.
“The divisions of Hematology and Oncology offer comprehensive management and treatment of inpatients as well as outpatients in the clinic and in the outpatient infusion center. The Adult Hematology provides comprehensive workup and treatment of both benign and malignant blood disorders including an Anticoagulation Clinic to assist physicians in optimizing the safety and efficacy of anticoagulation therapy. We have access to the most modern and updated treatment regimens including chemotherapy, targeted therapies as well as radio immunotherapy” said Dr. Mohammad Noshi, Acting Chairman of SKMC’s Medicine Institute.
Dr. Jorgen Kristensen, symposium organizer added, “At the Infusion Center and the Oncology and Hematology Divisions of SKMC, we offer chemotherapy, targeted therapies, transfusion of blood products, various infusion therapies including biological agents and bisphosphonate, and other related services for patients with thalassemia, sickle cell disease or other hemoglobinopathies, therapeutic phlebotomy, central line catheter care, therapeutic plasma exchange, blood exchange transfusion and procedures like lumbar puncture”.